Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to rescue platelet levels in leukemia patients

NCT ID NCT06898983

Recruiting now Disease control Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests a drug called romiplostim N01 in people with leukemia who develop dangerously low platelet counts from their cancer treatment. The goal is to see if weekly injections can safely raise platelet levels and reduce the need for transfusions. The study involves about 97 adults aged 18 to 75.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
romiplostim N01
What this could lead to
If successful, this could offer a new option to manage dangerously low platelet counts caused by leukemia treatment, potentially reducing the need for platelet transfusions.
What could go wrong
This is a Phase 2 trial with only 97 participants, so results are preliminary. The drug may not work for everyone and could have side effects like any medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER TREATMENT-INDUCED THROMBOCYTOPENIA (CTIT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER TREATMENT-INDUCED THROMBOCYTOPENIA (CTIT)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

    RECRUITING

    Hefei, Anhui, 230036, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.